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Abstract
Background: To compare the RapidArc plan for primary hepatocellular carcinoma (HCC) with 3-D conformal
radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT) plans using dosimetric analysis.
Methods: Nine patients with unresectable HCC were enrolled in this study. Dosimetric values for RapidArc, IMRT, and
3DCRT were calculated for total doses of 45~50.4 Gy using 1.8 Gy/day. The parameters included the conformal index
(CI), homogeneity index (HI), and hot spot (V107%) for the planned target volume (PTV) as well as the monitor units
(MUs) for plan efficiency, the mean dose (Dmean) for the organs at risk (OAR) and the maximal dose at 1% volume (D1%)
for the spinal cord. The percentage of the normal liver volume receiving ≥ 4 0 ,>3 0 ,>2 0 ,a n d>1 0G y( V 40 Gy,V 30 Gy,
V20 Gy,a n dV 10 Gy) and the normal tissue complication probability (NTCP) were also evaluated to determine liver toxicity.
Results: All three methods achieved comparable homogeneity for the PTV. RapidArc achieved significantly better CI
and V107% values than IMRT or 3DCRT (p < 0.05). The MUs were significantly lower for RapidArc (323.8 ± 60.7) and
3DCRT (322.3 ± 28.6) than for IMRT (1165.4 ± 170.7) (p < 0.001). IMRT achieved a significantly lower Dmean of the
normal liver than did 3DCRT or RapidArc (p = 0.001). 3DCRT had higher V40 Gy and V30 Gy values for the normal liver
than did RapidArc or IMRT. Although the V10 Gy to the normal liver was higher with RapidArc (75.8 ± 13.1%) than with
3DCRT or IMRT (60.5 ± 10.2% and 57.2 ± 10.0%, respectively; p < 0.01), the NTCP did not differ significantly between
RapidArc (4.38 ± 2.69) and IMRT (3.98 ± 3.00) and both were better than 3DCRT (7.57 ± 4.36) (p = 0.02).
Conclusions: RapidArc provided favorable tumor coverage compared with IMRT or 3DCRT, but RapidArc is not
superior to IMRT in terms of liver protection. Further studies are needed to establish treatment outcome
differences between the three approaches.
Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon malignancy and the third most common cause of
cancer-related death in the world [1]. Surgical resection
has been proven as the major treatment modality for
HCC. However, most patients with HCC have unresect-
able disease at diagnosis. These patients are treated with
other treatment modalities, such as percutaneous
ethanol injection (PEI), radiofrequency ablation (RFA)
therapy, transcatheter arterial chemoradiotherapy
(TACE), or sorafenib, but the response to treatment is
limited [2-6].
The use of radiation therapy (RT) for the treatment of
HCC was first investigated more than 40 years ago, but
the early trials reported poor results due to the low toler-
ance of the whole liver to radiation and severe hepatic
toxicity, or radiation-induced liver disease (RILD) caused
by whole liver irradiation [7,8]. RILD, a clinical syndrome
characterized by ascites, anicteric hepatomegaly, and
impaired liver function, is developed in 5% of patients
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usually occurs 2 weeks to 4 months after completion of
RT. RILD usually resolves after supportive care. Unfortu-
nately, severe RILD may develop into hepatic failure and
even death [9,10]. The low hepatic tolerance to radiation
also limits the application of higher radiation doses to
the tumor. In 1991, Emami et al. reported that the TD5/5
(the tolerance dose leading to a 5% complication rate at
5 years) for 1/3, 2/3, and the whole liver at 1.8~2 Gy/day
were 50 Gy, 35 Gy, and 30 Gy, respectively [11]. Dawson
et al used the normal tissue complication probability
(NTCP) of the Lyman model to describe the relationship
between irradiated liver volume and radiation dose and
they demonstrated that a higher radiation dose could be
delivered safely to liver tumors, with better outcomes, if
only part of the liver was irradiated [12]. As image-based
treatment planning and engineering has advanced, three-
dimensional conformal radiotherapy (3DCRT) was devel-
oped to irradiate the tumor accurately while minimizing
t h ed o s et ot h en o r m a ll i v e r .An u m b e ro fs t u d i e sh a v e
demonstrated encouraging results showing that a radia-
tion dose could be safely increased to part of the liver
using 3DCRT [13]. For example, Park et al. reported a
significant relationship between the total dose to the liver
tumor and the tumor response (< 40 Gy, 40-50 Gy, and >
50 Gy giving responses of 29.2%, 68.6%, and 77.1%,
respectively) without significant toxicity (rate of liver
toxicity: 4.2%, 5.9%, and 8.4%, respectively).
Despite improvements to 3DCRT, dose distribution
remains suboptimal in some cases. In the early 2000s, the
development of inverse planning systems and multileaf
collimators (MLCs) culminated in a more sophisticated
technique, intensity-modulated radiotherapy (IMRT).
Using an inverse planning algorithm to generate multiple
nonuniform-intensity beams, IMRT can potentially deli-
ver a higher dose to the tumor while delivering a rela-
tively lower dose to the normal liver as compared with
3DCRT. Cheng et al. suggested that IMRT might be able
to preserve acceptable target coverage and potentially
reduce NTCP values (IMRT = 23.7% and 3DCRT =
36.6%, p = 0.009) compared with 3DCRT [14]. Fuss et al.
reported that IMRT allowed a dose escalation to 60 Gy,
in which range 3DCRT had to reduce the total dose to
decrease the probability of RILD to acceptable levels [15].
The RapidArc technique, developed by Varian Medical
Systems about 2 years ago, is a volumetric intensity-
modulated arc therapy that accurately and efficiently
d e l i v e r sar a d i a t i o nd o s et ot h et a r g e tu s i n gao n e - o r
two-arc gantry rotation by simultaneously modulating
the MLC motion and the dose rates. RapidArc has been
shown to be equivalent or superior to IMRT for some
malignancies, including head and neck cancer and pros-
tate cancer [16-18], but there has been no study to
determine the feasibility of using RapidArc for the
treatment of primary HCC. The purpose of our study
was to compare the RapidArc radiation treatment plans
for patients with HCC with 3DCRT and IMRT plans
using dosimetric analysis. The PTV coverage and critical
organ sparing for each technique were determined using
dose-volume histograms (DVH) and the NTCP model.
Methods
Patient Characteristics
From April 2008 to July 2010, we enrolled nine patients
who had primary HCC diagnosed at China Medical Uni-
versity Hospital. All patients underwent alpha-fetoprotein
(AFP) examination, contrast-enhanced computed tomo-
graphy (CT), and ultrasonography to confirm the diagno-
sis. All patients were male and the median age was 57
years (range, 38-81 years). Five patients had Child-Pugh
score A cirrhosis and 4 had Child-Pugh score B cirrhosis.
Eight (88.9%) patients had American Joint Committee on
Cancer (6
th edition) stage III disease, and 1 (11.1%)
patient had stage IV disease.
Immobilization, Simulation, and Target Delineation
The patients were immobilized using vacuum casts in a
supine position with both arms raised above their heads.
Non-contrast CT simulation was performed with a 5-mm
slice thickness and included whole liver and bilateral kid-
ney scans. Respiratory control and abdominal compres-
sion were not used. After simulation, the CT images
were transferred into the Eclipse treatment planning sys-
tem (Version 8.6.15, Varian Medical System, Inc., Palo
Alto, CA, US), and target delineation was performed with
the aid of the contrast-enhanced CT images.
We defined the gross tumor volume (GTV) as the
volume of primary tumor evident on contrast-enhanced
CT images. The clinical target volume (CTV) was deli-
neated on the basis of the GTV expanded by 5 mm. The
planning target volume (PTV) was defined as the CTV
with a 5-mm radial expansion and a 10-mm craniocaudal
expansion to account for errors caused by the daily setup
process and internal organ motion. The normal liver
volume was defined as the total liver volume minus the
GTV. All of the contours were drawn by the same
physician.
Treatment Planning and Dose Delivery
In our study, we prescribed 95% of total dose to cover ≥
95% of the PTV coverage in daily 1.8-Gy fractions while
keeping the minimum dose ≥ 93% of total dose and
maximum dose ≤ 107% of total dose and normalized all
plans to the mean dose of PTV. The guidelines for dose
prescription were as follows. When the normal liver
volume irradiated with > 50% of the isocenter dose was
< 25%, 25-50%, or 50-75%, the total dose prescribed was
> 59.4 Gy, 45-54 Gy, and 41.4 Gy, respectively [19]. No
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for the organs at risk (OARs), can be seen in Table 1.
These were imposed in terms of the TD5/5 to ensure
that the maximal tolerated doses to the normal liver,
stomach, kidneys, and spinal cord were not exceeded
[11]. Six-or 10-MV photon beams were used, depending
on the tumor location, and the same energy was used
for each patient and for all three methods.
For each patient, three different plans (3DCRT, IMRT,
and RapidArc) were calculated using the Eclipse planning
system with the 120-leaf multi-leaf collimator (MLC) (Var-
ian Medical Systems). For the 3DCRT and IMRT plans, all
the gantry angles and numbers of radiation fields (range,
4-5) were manually selected on the basis of the morpholo-
gical relationship between the PTV and OARs to cover at
least 95% of the PTV and spare the OARs. A dose rate of
400 MU/min was used. For RapidArc, the plans were opti-
mized using the two-arc technique with gantry angle run-
ning counterclockwise from 179° to 181° and clockwise
from 181° to 179° and with the dose rate varied between 0
MU/min and 600 MU/min (upper limit). The optimization
constraints for OARs using RapidArc were the same as the
constraints in Table 1.
Plan Evaluation
1. PTV coverage
T h ed o s et ot h eP T Vw a se v a l u a t e du s i n gD V H s
with the following parameters:
a. Vx% means the volume receiving ≥ x% of the pre-
scribed dose. For example, the V100% of the PTV was
used to prescribe the PTV coverage, and V107% was
used to represent the hot spot in the PTV.
b. The conformity index (CI) = (VPTV/TVPV)/(TVPV/
VTV)=V PTV ×V TV/TVPV
2, where VPTV is the volume
of the PTV, TVPV is the portion of the VPTV within
the prescribed isodose line, and VTV is the treated
volume of the prescribed isodose line [17,20]. The CI
represented the dose fit of the PTV relative to the
volume covered by the prescribed isodose line. The
smaller and closer the value of CI is to 1, the better
the conformity of the PTV.
c. The homogeneity index (HI) = D5%/D95%,w h e r e
D5% and D95% are the minimum doses delivered to
5% and 95% of the PTV [17,21]. HI is a ratio that is
used to evaluate the homogeneity of the PTV. The
smaller and closer the value of HI is to 1, the better
the homogeneity of the PTV.
2. OARs sparing
a. VnGy is the percentage of organ volume receiving ≥
nG y .I nt h i ss t u d y ,V 40 Gy was the percentage of the
normal liver volume receiving ≥ 40 Gy, which repre-
sents high-dose exposure for the normal liver. In con-
trast, V10 Gy was the percentage of the normal liver
volume receiving ≥ 10 Gy, which represented low-
dose exposure for the normal liver.
b. We used the normal tissue complication probabil-
ity (NTCP), from the Lyman model, to measure the
probability of RT complications in the normal liver
[22]. In the NTCP model,
NTCP =
1
√
2π
 x
−∞
exp(−t2/2)dt =
1
2
[1 + erf(
x
√
2
)] (1)
x =
EUD − TD50(1)
m × TD50(1)
,EUD =


i
vi × (Di)
1/n
n
(2)
where EUD is the equivalent uniform dose, converted
from the dose-volume pairs [Di,v i], to describe the dose
which, if delivered uniformly to the entire organ, would
achieve the same effect as the given heterogeneous dose
distribution demonstrated by the DVH. The TD50(1) is
the dose to the whole liver that would result in a 50%
probability of toxicity. The parameter “m” is the steep-
ness of the dose-complication curve for a fixed partial
volume. The parameter “n” is the slope of the complica-
tion probability, which determines the dose-volume rela-
tionship for the irradiated normal liver. In this study, the
following values for the parameters were used: n = 0.32,
m = 0.15, and TD50(1) = 40 Gy [23].
Statistical Analyses
The dosimetric differences among the three treatments
for the nine patients were analyzed using the Friedman
test. When a significant difference (p < 0.05) was found,
the difference between two treatments for each effect
was further examined by Wilcoxon signed-rank test. All
analyses were performed using SPSS software, version
15.0 (SPSS Inc., Chicago, IL).
Results
PTV Coverage, CI, and HI
The mean gross tumor volume (GTV) was 979.3 ± 497.2
cm
3 (range, 346.5-2019.3 cm
3). The mean planned
tumor volume (PTV) was 1734.2 ± 923.0 cm
3 (range,
Table 1 The dose constraints of organ at risk
OAR Dose constraints
Normal liver Mean dose ≤ 26 Gy
Stomach Maximum dose ≤ 54 Gy
Kidney At least one side of kidney ≤ 23 Gy (mean dose)
Spinal cord Maximum dose ≤ 47 Gy
(Maximum dose of spinal cord plus 5-mm margin ≤ 45 Gy)
OAR: Organ at risk.
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3). The mean normal liver volume was
1632.4 ± 539.0 cm
3 (range, 933.7-2270.6 cm
3). None of
the PTVs included the whole liver. The prescribed total
dose was 49.4 ± 1.9 Gy (range, 45-50.4 Gy). The dose
rate of RapidArc varied between 0 MU/min and 461
MU/min. The typical dose distributions and dose-
volume histograms (DVH) for PTV and OARs are
s h o w ni nF i g u r e1a n d2 ,r e s pectively. In Figure 1C,
RapidArc achieved better conformality to the 95% iso-
dose line of the PTV than did 3DCRT and IMRT. In
addition, RapidArc also achieved better spinal cord spar-
ing to the 50% isodose line than did 3DCRT and IMRT.
However, RapidArc resulted in higher coverage at the
30% isodose line in the normal liver as compared with
3DCRT (Figure 1A) or IMRT (Figure 1B), which means
higher low-dose exposure occur for the normal liver
with RapidArc. In Figure 2, the right DVH showed that
all of the PTVs were fixed between V95% and V107%,
without any significant differences. The left DVH
showed that the low-dose distribution in the normal
liver was greater for RapidArc than for 3DCRT or
IMRT, and the high-dose distribution was greater for
3DCRT than for IMRT or RapidArc.
Table 2 summarizes the results for the investigated
DVH-parameters, including CTV coverage, PTV cover-
age, monitor unit (MU) dose and OAR dose for the 9
patients. Table 3 shows the differences among the
three methods with regard to the DVH parameters.
For target coverage, all V95% of CTV for these three
techniques gave at least 99% of the prescribed dose
without any significant difference (p =1 . 0 0 ) .F o rt h e
PTV coverage, the mean CI of RapidArc (1.12 ± 0.05)
was significantly lower than that of IMRT (1.19 ± 0.06)
and 3DCRT (1.286 ± 0.11) (p <0 . 0 5 ) .T h eV 95%,a n d
V100% valus for PTVs and HI were 95.50 ± 2.41, 76.81
± 5.95 and 1.13 ± 0.05 (3DCRT), 95.27 ± 1.99, 77.88 ±
4.27 and 1.13 ± 0.04 (IMRT), and 95.31 ± 1.64, 77.47
± 2.64 and 1.12 ± 0.03 (RapidArc), respectively, with
no significant differences among methods (p = 1.00,
1.00 and 0.69, respectively). For the hot spot sparing,
the mean V107% of the PTV was significantly highest
for 3DCRT (7.49 ± 7.92) and the lowest was RapidArc
(1.74 ± 2.82); this indicatest h a tt h e r ew a sb e t t e rh o t -
spot sparing of the PTV with RapidArc than with
IMRT or 3DCRT (p < 0.05).
OARs Sparing
The mean doses to the normal liver for each method
were 21.58 ± 3.01 Gy (3DCRT), 19.31 ± 2.89 Gy
(IMRT), and 21.97 ± 2.61 Gy (RapidArc), with a signif-
icantly lower mean dose to the normal liver with
IMRT than with 3DCRT or RapidArc (p < 0.05). The
high-dose regions of the normal liver were higher for
V40 Gy and V30 Gy with 3DCRT (23.05 ± 4.06 and
32.10 ± 6.80) than with IMRT (18.61 ± 4.13 and 26.23
±5 . 8 7 )( p < 0.01) or RapidArc (18.85 ± 3.97 and 27.77
± 5.34) (p < 0.05). The low-dose region of the normal
liver was higher for V10 Gy with RapidArc (75.77 ±
13.13) than with IMRT (57.24 ± 10.02) (p <0 . 0 1 )o r
3DCRT (60.55 ± 10.24) (p < 0.05). In Table 3, the
NTCP value for 3DCRT (7.57 ± 4.36) was significantly
higher than that for IMRT (3.98 ± 3.00) (p <0 . 0 1 )o r
RapidArc (4.38 ± 2.69) (p <0 . 0 5 ) ,b u tt h e r ew a sn o
significant difference in the NTCP between IMRT and
RapidArc (p = 0.26). For the other OARs, there were
no significant differences in dose among the three
methods, except for a lower mean dose to the stomach
and left kidney, respectively, with IMRT (20.63 ± 15.26
Gy and 8.36 ± 4.60 Gy) than with 3DCRT (23.16 ±
16.50 Gy and 11.37 ± 6.62 Gy) (p < 0.05). The maxi-
mum dose to the spinal cord (D1%) was equal for all
three methods.
Figure 1 The comparison of isodose distributions of PTV and OAR in 3DCRT, IMRT and RapidArc.A :3 D C R T ,B :I M R Ta n dC :R a p i d A r c .
RapidArc achieved better conformality to the 95% isodose line (red line) of the PTV and better spinal cord sparing to the 50% isodose line
(yellow line) as compared with 3DCRT and IMRT. However, RapidArc obtained higher 30%-isodose coverage (blue line) of volume of the normal
liver than did 3DCRT and IMRT.
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IMRT had three times the MUs (1165.44 ± 170.68) of
RapidArc (323.78 ± 60.65) and 3DCRT (322.33 ± 28.62)
(p < 0.01). There was no significant difference in the
numbers of MUs between 3DCRT and RapidArc (p =
0.859).
Discussion
Historically, the role of RT in HCC has been limited
because of the risk of RILD caused by whole liver irra-
diation. Improved knowledge of partial liver RT has cre-
ated renewed in using RT with HCC and, furthermore,
technical advancements in 3DCRT have allowed higher
doses to targeted to the tumors while minimizing expo-
sure of surrounding liver tissue. Recently, more and
more types of conformal RT have been developed to
deliver highly conformal treatment with minimal
damage to surrounding normal liver parenchyma,
including IMRT, image-guided radiotherapy (IGRT) and
stereotactic body radiotherapy (SBRT) [24]. RapidArc is
a novel form of volumetric intensity-modulated RT that
has the advantages of a short treatment time, fewer
MUs and the availability of highly conformal treatment
plans. Several investigations have demonstrated the
Figure 2 The comparison of DVHs for PTV and normal liver in 3DCRT, IMRT and RapidArc. Right figure = DVHs of PTV. These three
techniques produced similar homogeneity of the PTV. Left figure = DVHs of normal liver. RapidArc obtained the higher low-dose distribution in
the normal liver compared with 3DCRT and IMRT. On the other hand, 3DCRT obtained the high-dose distribution in the normal liver compared
with IMRT and RapidArc.
Table 2 The summary of all investigated DVH-parameters as mean values ± standard deviation (SD)
3DCRT IMRT RA
CTV V95% (%) 99.57 ± 0.39 99.65 ± 0.42 99.69 ± 0.42
PTV V95% (%) 95.50 ± 2.41 95.27 ± 1.99 95.31 ± 1.64
V100% (%) 76.81 ± 5.95 77.88 ± 4.27 77.47 ± 2.64
V107% (%) 7.49 ± 7.92 3.71 ± 3.00 1.74 ± 2.82
CI 1.286 ± 0.11 1.19 ± 0.06 1.12 ± 0.05
HI 1.13 ± 0.05 1.13 ± 0.04 1.12 ± 0.03
Normal liver Dmean (Gy) 21.58 ± 3.01 19.31 ± 2.89 21.97 ± 2.61
V40 Gy (%) 23.05 ± 4.06 18.61 ± 4.13 18.85 ± 3.97
V30 Gy (%) 32.10 ± 6.80 26.23 ± 5.87 27.77 ± 5.34
V20 Gy (%) 42.12 ± 7.56 37.16 ± 8.65 43.67 ± 8.18
V10 Gy (%) 60.55 ± 10.24 57.24 ± 10.02 75.77 ± 13.13
NTCP 7.57 ± 4.36 3.98 ± 3.00 4.38 ± 2.69
Stomach Dmean (Gy) 23.16 ± 16.50 20.63 ± 15.26 23.42 ± 13.70
Left Kidney Dmean (Gy) 11.37 ± 6.62 8.36 ± 4.60 7.69 ± 5.06
Right Kidney Dmean (Gy) 14.99 ± 13.11 13.11 ± 11.42 11.84 ± 10.41
Spinal Cord D1% (Gy) 38.94 ± 7.62 43.89 ± 2.01 38.51 ± 8.90
MU 322.33 ± 28.62 1165.44 ± 170.68 323.78 ± 60.65
PTV: planned tumor volume; MU: monitor unit; 3DCRT: 3-D conformal radiation therapy; IMRT: intensity-modulated radiation therapy; RA: RapidArc.
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that RapidArc achieved similar PTV coverage and OAR
sparing but lower MUs than IMRT in patients with
head and neck cancers. Besides, double arc plans yielded
better PTV coverage than single arc or IMRT [16].
Palma et al. reported that variable dose rate volumetric
modulated arc therapy achieved better dose distribution
and lower MUs than IMRT in patients with prostate
cancers. This work was a pilot study to investigate the
dosimetric difference of a RapidArc plan for HCC com-
pared to 3DCRT and IMRT plans.
In our study, the homogeneity of the PTV provided by
all three techniques was similar, but the RapidArc was
able to achieve better conformity and hot-spot sparing
of the PTV compared to IMRT or 3DCRT (p < 0.05).
For OARs sparing, the three methods showed compar-
able results in terms of the mean dose to the stomach
and kidneys and maximum dose to the spinal cord. For
the normal liver, 3DCRT provided the worst dose distri-
bution, with significantly worse Dmean,V 40 Gy,V 30 Gy,
and NTCP values than RapidArc or IMRT. Compared
with IMRT, RapidArc provided comparable V40 Gy,V 30
Gy, and NTCP values for the normal liver, but RapidArc
achieved significantly higher Dmean,V 20 Gy and V10 Gy
values for the normal liver.
The Lyman NTCP model has been widely used to pre-
dict or estimate the probability of normal tissue complica-
tion. This model supposed there is a sigmoid relationship
between a uniform radiation dose given to a part of the
volume in an organ and the probability of complication.
More and more authors have used this model to predict
RILD. Burman et al. assigned the parameters to be as fol-
lows, n as 0.32, m as 0.15, and TD50(1) as 40 Gy, in a
model that predict the risked of RILD [23]. Cheng et al.
applied the values of n = 0.35, m = 0.35 and TD50(1) =
49.4 Gy in another model [25]. Dawson et al. further mod-
ified the parameter TD50(1) to 39.8 Gy for hepatobiliary
cancer and to 45.8 Gy for liver metastasis (n = 0.97 and m
= 0.12) [26]. Although different values for the parameters
have been applied to the Lyman NTCP model by different
authors, they demonstrated the feasibility of partial liver
irradiation. If the TD50 is kept constant, the NTCP value
is represented as a function of partial volume. This organ
demonstrates a “threshold type behavior” and the NTCP
value will rise only if a certain volume is irradiated.
Furthermore, the NTCP value of the partial volume
depends on the dose. Therefore, we believe that the V40 Gy
and V30 Gy influence the NTCP values of the normal liver
more than V20 Gy and V10 Gy do. In addition, Dawson et
al. also addressed whether those who had impaired liver
Table 3 All differences among three methods with regard to the DVH-parameters
P value
Overall IMRT vs 3DCRT IMRT vs RA RA vs 3DCRT
CTV
V95% (%) 1.00 –– –
PTV
V95% (%) 1.00 –– –
V100% (%) 1.00 –– –
V107% (%) 0.016 – RA < IMRT * RA < 3DCRT *
CI 0.004 IMRT < 3DCRT * RA < IMRT * RA < 3DCRT *
HI 0.69 –– –
Normal liver
Dmean (Gy) 0.001 IMRT < 3DCRT * IMRT < RA * –
V40 Gy (%) 0.004 IMRT < 3DCRT ** – RA < 3DCRT *
V30 Gy (%) 0.004 IMRT < 3DCRT ** – RA < 3DCRT *
V20 Gy (%) 0.004 IMRT < 3DCRT ** IMRT < RA * –
V10 Gy (%) 0.007 – IMRT < RA ** 3DCRT < RA *
NTCP 0.002 IMRT < 3DCRT ** – RA < 3DCRT *
Stomach Dmean (Gy) 0.121 IMRT < 3DCRT * ––
Left Kidney Dmean (Gy) 0.085 IMRT < 3DCRT * ––
Right Kidney Dmean (Gy) 0.217 –– –
Spinal Cord D1% (Gy) 0.236 –– –
MU 0.001 3DCRT < IMRT ** RA < IMRT ** –
p < 0.05; ** p < 0.01.
PTV: planned tumor volume; Vx%: the volume receiving ≥ x% of the prescribed dose; VnGy: the percentage of organ volume receiving ≥ n Gy; CI: conformity
index; HI: homogeneity index; Dmean: the mean dose for the organ; D1%: the maximal dose at 1% volume for the organ; MU: monitor unit; 3DCRT: 3-D conformal
radiation therapy; IMRT: intensity-modulated radiation therapy; RA: RapidArc.
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model and whether a better understanding of the mechan-
ism of RILD may improve the accuracy of Lyman model
in the future.
In addition to value used for NTCP, the V30 Gy and
Dmean of the normal liver play important roles in pre-
dicting the risk of RILD. Dawson et al.d e m o n s t r a t e d
that the Dmean of normal liver was associated with the
risk of RILD [26]. Yamada et al. reported a deterioration
in the Child-Pugh Score in 5 out of 6 patients with a
V30 Gy >4 0 % ,vs. 2 of 13 patients with a V30 Gy <4 0 %
(p < 0.01) [27].
Another issue that should be kept in mind is the
higher low-dose irradiation to normal liver compared
w i t h3 D C R To rI M R Tw h e nR a p i d A r ci su s e d .S h u e n g
et al. published a case of cholangiocarcinoma with bone
metastasis who had received palliative RT for bone pain
who developed radiation pneumonitis [28]. They
demonstrated that, in this case, although the V5G yof
the normal lung was only 20%, this still potentially
induced radiation pneumonitis. One of the possible
causes is an interaction between radiation-induced
inflammation within the previously irradiated field and
chemotherapy. Yamashita et al. has reported that the
incidence of lung toxicity will become higher if large
amount of low dose radiation is delivered [29]. In addi-
tion to the dosimetric impact, several investigators
reported that some biological factors are associated with
RILD. For example, Cheng et al. reported that the HBV
carriers or cases with Child-Pugh B cirrhosis were corre-
lated with the risk of RILD after 3D-CRT [25]. Xu et al.
also reported that the Child-Pugh classification was
associated with RILD [30]. In the current study, the
potential risk of RILD caused by low-dose irradiation is
unclear, but HCC patients in Taiwan usually have hepa-
titis B or C infection and liver cirrhosis and they usually
received TACE, PEI or targeted therapy before RT.
Radiation oncologists should be aware of the potential
risk of higher low-dose exposure to the normal liver
when RapidArc is used.
From the view of dosimetric comparison, one of the
reasons that RapidArc is not better than IMRT for liver
protection may be that HCC is always surrounded by
normal liver parenchyma, which is the major concern
when using the volumetric RapidArc technique. In our
study, we found that RapidArc increased the V10 Gy,V 20
Gy and Dmean of the normal liver compared to IMRT
and, therefore, we suggest that the RapidArc should be
used more carefully when treating HCC cases even if
both RapidArc and IMRT achieve equivalent V30 Gy for
the normal liver and have similar NTCP values.
Another advantage of RapidArc over IMRT were the
reduction in the number of MUs. Several studies have
reported that the disadvantages of IMRT include higher
MUs, longer delivery times, and more low-dose expo-
sure of organs at risk (OARs), all of which increase the
risk of a radiation-induced second malignancy. Hall
reported that IMRT, as compared with 3DCRT, might
double the incidence of solid cancers in long-term survi-
vors, especially children [31]. Zwahlen studied the can-
cer risk after IMRT for cervical and endometrial cancer
and reported that cumulative second cancer risks (SCR)
relative to 3DCRT for 6-MV and 18-MV IMRT plans
were +6% and +26%, respectively [32]. There is no suffi-
cient data to demonstrate that the lower MUs associated
with RapidArc might reduce the risk of radiation-
induced second malignancy. Furthermore, radiation-
induced second malignancy occurs only in those who
have long-term survival after treatment. Xu et al.
reported that the 5-year survival rate for HCC patients
receiving TACE plus RT was only 13% with a median
survival time of 18 months [33]. Thus this advantage of
RapidArc may have little influence on the prevention of
radiation-induced second malignancy for HCC patients.
Verbakel WF et al.[ 1 6 ]a n dW a g n e ret al.[ 3 4 ]c o m -
pared RapidArc with IMRT for different malignancies
and concluded that the major advantages of RapidArc
over IMRT were the lower MUs and the shorter treat-
ment time, which can be beneficial to the reduction of
intra-fractional movement, improving patient comfort,
and higher patient throughput.
Although RapidArc has been demonstrated the advan-
tages on the treatment of other kinds of malignancies, the
dosimetric advantage of RapidArc in our study is not
always better than IMRT. Therefore it is not convincing
that IMRT should be replaced by RapidArc when treating
HCC. The limitations of our study include small patient
numbers, relatively coarse 5 mm-slice thickness and a lack
of respiratory control or abdominal compression. These
limitations would possibly cause some errors in the dose
calculation and analysis. Clinical trials and long-term fol-
low-up are required to draw more definite conclusions.
Therefore, we suggest that if PTV conformity and percen-
tages of NTCP, Dmean,V 30 Gy and V10 Gy of the normal
liver are acceptable, RapidArc may be selected on the basis
of fewer MUs. If PTV coverage is not adequate or each of
the above parameters related to liver toxicity is too high
with RapidArc, then IMRT should be used.
In conclusion, RapidArc obtained favorable tumor
coverage compared with IMRT and both RapidArc and
IMRT achieved significantly better quality in terms of
treatment plan when compared with 3DCRT. However,
RapidArc is not superior to IMRT for liver protection.
Nonetheless, RapidArc is a new technique, and optimi-
zation of its algorithm is still in its early stages (about 2
years of clinical experience), whereas 3DCRT and IMRT
have been well-investigated and routinely used for more
than 10 years. It is expected that more comprehensive
Kuo et al. Radiation Oncology 2011, 6:76
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Page 7 of 9planning systems for RapidArc are being developed and
these might advance the optimization process in the
future.
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